Are you Dr. Gujrathi?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 45 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
50 Ivy St
San Francisco, CA 94102Phone+1 415-355-7400
Summary
- Dr. Sheila Gujrathi, MD is an internist in San Francisco, California. She is currently licensed to practice medicine in California.
Education & Training
Stanford Health Care-Sponsored Stanford UniversityFellowship, Rheumatology, 1998 - 2001
Brigham and Women's HospitalResidency, Internal Medicine, 1999 - 2000
Northwestern University The Feinberg School of MedicineClass of 1996
Certifications & Licensure
CA State Medical License 1998 - 2026
Publications & Presentations
PubMed
- 156 citationsRPC4046, a Monoclonal Antibody Against IL13, Reduces Histologic and Endoscopic Activity in Patients With Eosinophilic Esophagitis.Ikuo Hirano, Margaret H. Collins, Yehudith Assouline-Dayan, Larry Evans, Sandeep K. Gupta
Gastroenterology. 2019-02-01 - 35 citationsCardiac Safety of Ozanimod, a Novel Sphingosine-1-Phosphate Receptor Modulator: Results of a Thorough QT/QTc Study.Jonathan Q. Tran, Jeffrey P. Hartung, Allan Olson, Boaz Mendzelevski, Gregg Timony
Clinical Pharmacology in Drug Development. 2018-03-01 - 71 citationsResults From the First-in-Human Study With Ozanimod, a Novel, Selective Sphingosine-1-Phosphate Receptor Modulator.Jonathan Q. Tran, Jeffrey P. Hartung, Robert Peach, Marcus F. Boehm, Hugh Rosen
Journal of Clinical Pharmacology. 2017-08-01
Press Mentions
Ventyx Biosciences Lines up $100M IPO with Busy Clinical Schedule AheadSeptember 30th, 2021- With Maverick Now in Takeda's Hands, James Scibetta Turns the Page; Roivant CMO Leaves in Favor of Small IL-2 BiotechSeptember 24th, 2021
- Ventyx Biosciences Snags $51M, Hires New CMO from Horizon TherapeuticsSeptember 20th, 2021
- Join now to see all
